Key facts
- This page summarizes Anthony P. Mack's Form 4/A - Amendment filing for Virpax Pharmaceuticals, Inc. (VRPX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 07 Feb 2023, 20:30.
Anthony P. Mack - 25 Jan 2023 Form 4/A - Amendment Insider Report for Virpax Pharmaceuticals, Inc. (VRPX)
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- VRPX
- Reported as of
- 25 Jan 2023
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 07 Feb 2023, 20:30:11 UTC
- Original report date
- 27 Jan 2023
- Prior SEC filing
- 20 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Chipman, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anthony P. Mack filed Form 4/A - Amendment for Virpax Pharmaceuticals, Inc. (VRPX) on 07 Feb 2023.
Change
- Previous filing in this sequence was filed on 20 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRPX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +125,000
- Change %
- Price
- $0.000000
- Shares after
- 125,000
- Date
- 25 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125,000
- Exercise price
- $0.8670
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests in three equal annual installments commencing on January 25, 2024.
SEC remarks
This amendment on Form 4/A is being filed to amend the Form 4 filed on January 27, 2023, solely to correct inadvertent errors in the exercise price and expiration date of the Stock Option previously reported in Column 2 and Column 6 of Table II, respectively.